Genetics and Pain Severity in Sickle Cell Disease
Public ClinicalTrials.gov record NCT01441141. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Background: \- Pain is the most common symptom of sickle cell disease. Episodes of severe sickle cell pain are known as "crises." High rates of pain crises are associated with a higher risk of early death. Some people with sickle cell disease have many severe pain crises while others experience fewer crises. This difference in pain crisis may be caused by sensitivity to pain. People with high sensitivity to pain may have more pain crises. Many factors, including a person's genetic makeup, determine sensitivity to pain. Comparing genetic information from people with sickle cell disease and healthy volunteers may provide more information on pain and sickle cell disease. Objectives: \- To study genetics and pain sensitivity in sickle cell disease. Eligibility: * African or African American individuals at least 18 years of age with sickle cell disease. * Healthy African or African American volunteers at least 18 years of age. Design: * Participants will be screened with a medical history and physical exam. They will also provide blood and urine samples. * Participants will have the following tests: * Quantitative sensory testing to measure sensitivity to pressure, heat, cold, and mechanical pain. * EndoPat test to measure blood vessel function and reaction. * Questionnaires about mood, evidence of depression, pain, quality of sleep, and sleep disturbances. * Measures of daily pain, whether or not related to sickle cell disease. * After the first visit, those in the study will have monthly study visits for 6 months. The above tests will be repeated at these visits.
Study identification
- NCT ID
- NCT01441141
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 67 participants
Conditions and interventions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 16, 2012
- Primary completion
- May 30, 2016
- Completion
- Dec 8, 2020
- Last update posted
- Dec 9, 2020
2012 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01441141, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2020 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01441141 live on ClinicalTrials.gov.